Pirs stock zacks
14 Nov 2019 Pier 1 Imports (NYSE:PIR) stock price is settled at $6.58 in last trading activity. Having a look at the daily price change trend and size of price These returns cover a period from January 1, 1988 through December 2, 2019. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. Pieris Pharmaceuticals (PIRS) Reports Q3 Loss, Tops Revenue Estimates Pieris Pharmaceuticals (PIRS) delivered earnings and revenue surprises of 78.26% and 141.15%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock? Find the latest Pieris Pharmaceuticals, Inc. (PIRS) stock quote, history, news and other vital information to help you with your stock trading and investing. Here are some recent quotes from research analysts about Pieris Pharmaceuticals stock: 1. According to Zacks Investment Research, "Pieris Pharmaceuticals, Inc. is a biopharmaceutical company. The Company's drug technology consists of Anticalin(R) to treat cancer, severe asthma, anemia and other medical conditions. Get breaking news and analysis on Pieris Pharmaceuticals, Inc. (PIRS) stock, price quote and chart, trading and investing tools. Pieris is in an upward channel and looking bullish. Analyst ratings on the stocks aren't great, but Zacks has given it a HUGE Earnings Surprise Prediction (13.25%!), which should help the stock continue its run until the next report date in early August. Be aware, however, that it is approaching some stiff resistance above $4.60.
Find the latest Pieris Pharmaceuticals, Inc. (PIRS) stock quote, history, news and other vital information to help you with your stock trading and investing.
Pfizer (NYSE:PFE) stock hasn't been a big winner so far in 2018. On the other hand, the big pharma stock is beating the S&P 500 index at this point. Forex for beginners amazon ### Forex Pairs Hedging Forex signal plugin wordpress cookies ### Forex 8mm fisheye pictures View Anika Therapeutics Inc. ANIK investment & stock information. Get the latest Anika Therapeutics Inc. ANIK detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. View Coherus BioSciences, Inc. CHRS investment & stock information. Get the latest Coherus BioSciences, Inc. CHRS detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Exploring Park City Group (Nasdaq:PCYG) stock? View PCYG's stock price, price target, earnings, financials, forecast, insider trades, news, and SEC filings at MarketBeat.
View the latest Pieris Pharmaceuticals Inc. (PIRS) stock price, news, historical charts, analyst ratings and financial information from WSJ.
Stock Price Forecast. The 2 analysts offering 12-month price forecasts for Pier 1 Imports Inc have a median target of 15.00, with a high estimate of 20.00 and a Real time Pier 1 Imports (PIR) stock price quote, stock graph, news & analysis. PIRS / Pieris Pharmaceuticals, Inc. Institutional Ownership. File Date, Form, Investor, Opt, Avg Share Price, Shares, Shares Changed (%), Value ($1000)
Top trades and best-performing strategies with Pieris Pharmaceuticals, Inc. $PIRS supported by the most actionable news from the market.
The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise Stockopedia rates Pieris Pharmaceuticals Inc as a Adventurous Sucker Stock . 3 brokers rate it as a 'Buy'. Click to view NAQ:PIRS's StockReport.
Top trades and best-performing strategies with Pieris Pharmaceuticals, Inc. $PIRS supported by the most actionable news from the market.
Optex price list The markets are relatively flat ahead of the FOMC Meeting today, but some stocks are moving, and here are some small cap stocks traders are watching today. Pfizer (NYSE:PFE) stock hasn't been a big winner so far in 2018. On the other hand, the big pharma stock is beating the S&P 500 index at this point.
Stock quote for Pieris Pharmaceuticals, Inc. Common Stock Common Stock (PIRS) with real-time last sale and extended hours stock prices, company news, charts, and Pieris Pharmaceuticals holds a buy signal from the short-term moving average; at the same time, however, a sales signal from the long-term average. Since the longterm average is above the short-term average there is a general sales signal in the stock. On further gains, the stock will meet resistance from the long-term moving average at $3.63. PIRS, Pieris Pharmaceuticals - Stock quote performance, technical chart analysis, SmartSelect Ratings, Group Leaders and the latest company headlines 5/24/2019 · Zacks Investment Research downgraded shares of Pieris Pharmaceuticals (NASDAQ:PIRS) from a hold rating to a sell rating in a research note released on Thursday, Zacks.com reports. According to Zacks, “Pieris Pharmaceuticals, Inc. is a biopharmaceutical company. 5/23/2019 · Pieris Pharmaceuticals (NASDAQ:PIRS) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Thursday, Zacks.com reports. According to Zacks, “Pieris Pharmaceuticals, Inc. is a biopharmaceutical company. 11/11/2019 · Pieris Pharmaceuticals (PIRS) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to loss of $0.11 per share a year ago. These figures are adjusted for non-recurring items. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $5.64 to $6.37 in the past one-month time frame. The company has seen no changes when it comes to estimate revision over the past few weeks, while the Zacks Consensus Estimate for the current quarter has also remained unchanged.